Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer.
Publication
, Conference
Nagata, H; Osada, T; Crosby, EJ; Canton, DA; Twitty, CG; Lyerly, HK
Published in: CANCER RESEARCH
2021
Duke Scholars
Published In
CANCER RESEARCH
EISSN
1538-7445
ISSN
0008-5472
Publication Date
2021
Volume
81
Issue
13
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Nagata, H., Osada, T., Crosby, E. J., Canton, D. A., Twitty, C. G., & Lyerly, H. K. (2021). Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer. In CANCER RESEARCH (Vol. 81).
Nagata, Hiroshi, Takuya Osada, Erika J. Crosby, David A. Canton, Chris G. Twitty, and H Kim Lyerly. “Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer.” In CANCER RESEARCH, Vol. 81, 2021.
Nagata H, Osada T, Crosby EJ, Canton DA, Twitty CG, Lyerly HK. Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer. In: CANCER RESEARCH. 2021.
Nagata, Hiroshi, et al. “Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer.” CANCER RESEARCH, vol. 81, no. 13, 2021.
Nagata H, Osada T, Crosby EJ, Canton DA, Twitty CG, Lyerly HK. Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer. CANCER RESEARCH. 2021.
Published In
CANCER RESEARCH
EISSN
1538-7445
ISSN
0008-5472
Publication Date
2021
Volume
81
Issue
13
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis